Unreliability of Current Serum Fibrin Degradation Product (FDP) Assays

Summary

Previously, assays of fibrin-fibrinogen degradation products (FDP) had to be performed on serum samples. However, monoclonal antibodies (Mabs) are now available which permit the measurement of FDP directly in plasma. We have employed two Mabs, one monospecific for FDP originating from crosslinked fibrin and another panspecific for the FDP fraction, to determine normal FDP levels in plasma and serum. The monospecific Mab gave a value of 40 ng FDP/ml in plasma and 10 ng/ml in serum, while the serum level of FDP recorded using the panspecific Mab was >1000 ng/ml, at all the concentrations of thrombin employed. Similarly, when a solution of purified fibrinogen was treated with thrombin, the concentration of FDP present in the clot supernatant was >1000 ng/ml when assayed using the panspecific Mab. Thus during serum preparation as much as 75% of the native FDP is incorporated into the clot while in excess of 1000 ng/ml of laboratory generated FDP, probably incompletely polymerized fibrin, is measured using panspecific antisera. These data indicate that current FDP assays using polyclonal antibodies are not a reliable reflection of the FDP level generated in vivo. The use of FDP-specific Mabs which do not react with fibrinogen is recommended for future FDP assays performed directly on plasma.

Keywords

Fibrin degradation products - Monoclonal antibodies

• References

• 1 Gaffney PJ. Fibrin fragmentation by plasmin: molecular considerations and their relevance to DIC and thrombosis. In Fibrinogen: Recent biochemical and medical aspects. Henschen A, Graeff H, Lottspeich F. (eds) Walter de Gruyter; Berlin: 1982
• 2 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
• 3 Gaffney PJ, Brasher M, Lord K, Strachan CJ L, Wilkinson AR, Kakkar VV, Scully MF. Fibrin sub-units in venous and arterial thromboembolism. Cardio-vasc Res 1976; 10: 421-426
• 4 Pisano JJ, Finlayson JS, Petyon MP, Nagai Y. Epsilon (γ-glutamyl) lysine in fibrin: lack of crosslink formation in factor XIII deficiency. Proc Natl Acad Sci USA 1971; 68: 770-772
• 5 Donati MB. Assays for fibrinogen/fibrin degradation products in biological fluids: some methodological aspects. Thrombos Diathes Haemorrh 1975; 34: 652-660
• 6 Chen JP, Schulof RS. Radioimmunoassay of fibrinogen-fibrin degradation products: assay for fragment E-related neoantigen-methodological aspects. Thromb Res 1979; 16: 601-615
• 7 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemostas 1983; 50: 591-594
• 8 Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
• 9 Gaffney PJ. The occurrence and clinical relevance of fibrin fragments in blood. Ann NY Acad Sci 1983; 408: 407-421
• 10 Graeff H, Hafter R. Selection and relevance of crosslinked fibrin derivatives in blood. Semin Thromb Haemostas 1982; 8: 57-68
• 11 Nossel HL, Yudelman I, Canfield RE, Butler jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 45-53
• 12 Merskey C, Johnson AJ, Lalezari P. Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin. J Clin Invest 1972; 51: 903-911
• 13 Gaffney PJ, Mahmoud M, Joe F. Giant fibrin fragments derived from crosslinked fibrin: structure and clinical implications. Thromb Res 1980; 20: 647-662